Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline ...
For decades, 7+3—consisting of cytarabine plus an anthracycline—has been the backbone of induction therapy for fit adults ...
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) KOL Interview - US, South" report has been added to ResearchAndMarkets.com's offering. This report presents an exclusive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results